ASTCT Pharmacy SIG Journal Club - June 2025

The ASTCT Pharmacy SIG June 2025 Journal Club will air on Wednesday, June 11 at 2 pm CT/3 pm ET.This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q & A session. In the June Journal Club session, Drs. Aljundi and Henderson will present two articles related to:

1. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
2. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy

Presenters & Articles:

Alisar Aljundi, PharmD

PGY-2 Pharmacy Resident

Barnes-Jewish Hospital

Article: Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Jonathan Henderson, PharmD

PGY-2 Pharmacy Resident

Baylor University Medical Center

Article: Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Review current standard of care approaches to GVHD prophylaxis in the haploidentical transplant setting.
• Analyze safety and efficacy of itacitinib prophylaxis for prevention of GVHD and CRS in haploidentical transplant.
• Assess feasibility and functionality of implementation of itacitinib prophylaxis in haploidentical transplant.
• Review the pathophysiology of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD) and the clinical challenges associated with its management in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients.
• Analyze the safety and efficacy outcomes of tabelecleucel for the treatment of relapsed or refractory EBV-positive PTLD.
• Evaluate the role of tabelecleucel as a treatment option for patients with EBV-positive PTLD in both relapsed/refractory and future frontline settings.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full CE information for this session will be available soon.